Clinical Trial of DNA Decoy to Make Ovarian Cancer’s Zejula More Effective Set to Open

Clinical Trial of DNA Decoy to Make Ovarian Cancer’s Zejula More Effective Set to Open
A Phase 1b/2 clinical trial testing Onxeo’s AsiDNA as a potential treatment to overcome resistance to Zejula (niraparib) in ovarian cancer patients is set to begin, part of an agreement between Onxeo and Gustave Roussy, a leading European cancer center. The REVOCAN trial plans to enroll 26 women who have been using Tesaro's Zejula as a second-line maintenance therapy for at least six months, and who experienced an elevation in the ovarian cancer biomarker CA125. This rise may signal the cancer is progressing while on Zejula. Led by Patricia Pautier at Gustave Roussy, the trial aims to achieve a drop in CA125 levels after the addition of AsiDNA to Zejula, suggesting that resistance has been overcome. Survival and time to disease progression will also be assessed as main efficacy outcomes. Researchers expect to enroll its first patients by June, and to present the first findings by year's end. "Gustave Roussy and Onxeo will conduct an original proof-of-concept study of the reversion of the mechanism of resistance to a major therapeutic class," Pautier, MD, oncologist, head of the Gynecological Cancers Committee at Gustave Roussy, said in a press release. "If positive, this first study ... may pave the way for further combination studies with this therapeutic class, in ovarian cancer but also in other pathologies, and offer patients who benefit from these treatments an additional opportunity to control their disease," she added. As cancer cells divide at a faster pace, they are prone to accumulating more errors in their genome than healthy cells. Cells have a specific machinery — called DNA Damage Response (DDR) — dedicated to finding these errors and correcting them, preventing additional cellular damage. Among the critical components of this co
Subscribe or to access all post and page content.